Drug Trial Radar · NCT05470868
Safety and Tolerability of PRO-185
Last checked: Nov 19, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Feb 4, 2023
Primary completion
May 22, 2023
Study completion May 22, 2023
Sponsor
- Lead sponsor
- Laboratorios Sophia S.A de C.V.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase I Study to evaluate safety and tolerability of PRO-185 (naphazoline/hypromellose) ophthalmic solution through evaluation of vital signs, ocular signs such as intraocular pressure, hyperemia and mydriasis and adverse events.
Conditions
- Hyperemia Eye
Interventions
Naphazoline / Hypromellose OphthalmicDrug
Naphazoline 0.03% / Hypromellose 0.2%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular Pressure (IOP) IncrementTime frame: Baseline visit (BV), day 1(pre and post pupil dilation); Visit 1 (V1), day 3 +1 (pre and post research product application); Visit 2 (V2), day 8 (pre and post research product application); Final Visit, day 10 (+1)
- Heart Rate IncrementTime frame: Baseline visit, day 1(pre and post pupil dilation); Visit 1, day 3 +1 (pre and post research product application); Visit 2, day 8 (pre and post research product application); Final Visit, day 10 (+1)
- Blood Pressure Increment (Systolic)Time frame: Baseline visit, day 1(pre and post pupil dilation); Visit 1, day 3 +1 (pre and post research product application); Visit 2, day 8 (pre and post research product application); Final Visit, day 10 (+1)
- Incidence of Conjunctival HyperemiaTime frame: Trough Day 10 (+1)
- Incidence of Pharmacological MydriasisTime frame: Trough Day 10 (+1)
- Blood Pressure Increment (Diastolic)Time frame: Baseline visit, day 1(pre and post pupil dilation); Visit 1, day 3 +1 (pre and post research product application); Visit 2, day 8 (pre and post research product application); Final Visit, day 10 (+1)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
IIMET Investigación e Innovación en Medicina Translacional
Guadalajara, Jalisco, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.